Table 1 Phase I/II clinical trials in oestrogen receptor-positive metastatic breast cancer
From: New targets for therapy in breast cancer: Farnesyltransferase inhibitors
Combination | Clinical setting | Number of patients | Primary end-point | Trial group |
|---|---|---|---|---|
Tipifarnib + Tamoxifen | Hormone responsive/hormone nonresponsive cancer | 52 | PK/PD | National Cancer Institute |
Tipifarnib + Tamoxifen | Post tamoxifen | 40 | ORR | H Roche (Toulouse) |
Tipifarnib + Tamoxifen | 2nd line: post tamoxifen or aromatase inhibitor | 45 | CBR | National Cancer Institute |